Richard T. Maziarz, MD

Articles

Final Thoughts: GVHD

July 30th 2021

All panelists provide their final thoughts on the current landscape and future directions in graft-vs-host disease (GVHD).

Steroid-Refractory Chronic GVHD

July 30th 2021

Sophie Paczesny, MD, PhD, provides an overview of the drug ibrutinib for use in steroid-refractory chronic graft-vs-host disease (GVHD). She elicits thoughts from the panelists on how they envision this drug being used.

Steroid-Refractory Acute GVHD

July 30th 2021

Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.

Steroid Refractory GVHD: Scope of the Problem

July 23rd 2021

Dr Chen provides an overview of the prevalence of steroid refractory GVHD and leads a discussion on how steroid refractory GVHD is defined.

Management of Chronic GVHD

July 23rd 2021

Dr Cutler leads a discussion on the approach to management of chronic GVHD and whether complete response is a realistic end point.

Management of Acute GVHD

July 16th 2021

Yi-Bin Chen, MD, leads a discussion on systemic treatment approaches being used currently for the management of acute graft-vs-host disease, as well as those being considered for the future.

Diagnosing & Staging of GVHD

July 16th 2021

Sophie Paczesny, MD, PhD, leads a discussion on diagnostic tests used in the setting of graft-vs-host disease and how patients are risk stratified. Whether organ biopsies are used routinely is also discussed.

GVHD Prophylaxis

July 9th 2021

Richard Maziarz, MD, highlights the fact that graft-vs-host disease (GVHD) is a T-cell disease and then outlines qualitative and quantitative mechanisms that are used to prophylactically target the alloreactive T-cell population. A calcineurin inhibitor combined with methotrexate is the currently accepted standard of care for GVHD prophylaxis. Panelists weigh in on the use of post-transplant cyclophosphamide (PTCy) for prevention of GVHD.

Immunopathology and GVHD Incidence

July 9th 2021

Yi-Bin Chen , MD, provides an overview of how the landscape graft-vs-host disease (GVHD) has evolved over the past 3 decades. Corey Cutler, MD, PhD, FRCPC, provides an overview of GVHD biology. Potential risk factors for development of acute and chronic GVHD are discussed.

Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCL

June 4th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Maziarz on Sustained Responses With Tisagenlecleucel in DLBCL

February 20th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

Dr. Maziarz Discusses Promise of Tisagenlecleucel in DLBCL

February 2nd 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses the promise of tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.